Partex.AI and LeadXpro Announce Collaboration to Expand Indications and Support Out-Licensing of A2BR Antagonist Program

Eschborn, Germany and Villigen, Switzerland — 27/01/2026 —

Partex.AI (“Partex”), an AI-driven therapeutic asset incubator and accelerator, and LeadXpro

AG (“LeadXpro”), a Switzerland-based pharmaceutical research and development company,

today announced that they have entered into a collaboration agreement focused on expanding

the therapeutic potential and supporting the future out-licensing of LeadXpro’s adenosine A2B

receptor (A2BR) antagonist program.

Under the agreement, Partex will apply its proprietary AI platform to identify and prioritize new

therapeutic indications beyond LeadXpro’s current development focus and support the

identification of potential licensing partners and downstream partnering activities. LeadXpro will

continue to lead research and preclinical development, contributing its expertise in medicinal

chemistry and translational drug development. Dr. Frank Grams, Chief Commercial Officer of

Partex, noted that the collaboration reflects Partex’s commitment to expanding the value of

promising assets by combining data-driven insights with its global partnering network to support

future licensing opportunities.

A2BR antagonists are a well-validated therapeutic class with applications across immuno-

oncology, inflammation, and central nervous system disorders. By combining LeadXpro’s

discovery know-how with Partex’s analytical and partnering capabilities, the collaboration aims

to accelerate strategic decision-making, refine indication positioning, and efficiently advance

partnering opportunities. Dr. Michael Hennig, Chief Executive Officer of leadXpro, added that

Partex brings strong analytical capabilities and transaction experience that support leadXpro’s

efforts to explore new indications and position the program for future partnering, while allowing

the company to remain focused on advancing the science.

About Partex N.V.

Partex N.V. is a public company incorporated under the laws of the Netherlands and registered

with the Netherlands Chamber of Commerce under KVK number 85275549. The Company’s

principal place of business is at Frankfurter Strasse 27, 65760 Eschborn, Germany. Partex is

engaged in AI-based drug discovery and has developed a proprietary technology platform that

delivers diverse recommendations on alternative targets, indications, and development

strategies to accelerate and de-risk pharmaceutical R&D.

About LeadXpro AG

LeadXpro AG is a private corporation (Aktiengesellschaft, CH-400.3.440.536-2) incorporated

under the laws of Switzerland, with its principal location of business at Park Innovaare,

Parkstrasse 1, CH-5234 Villigen, Switzerland. LeadXpro is engaged in the enablement of

structure- based drug discovery with a strong focus on translating innovative science into high-

quality drug candidates.